100 related articles for article (PubMed ID: 15013337)
1. Angiotension converting enzyme inhibition and calcium channel blockage improves cyclosporine induced glucose intolerance in rats.
Yavuz DG; Tuğlular S; Koçak H; Atakan A; Ozener C; Akoğlu E; Akalin S
Transplant Proc; 2004; 36(1):171-4. PubMed ID: 15013337
[TBL] [Abstract][Full Text] [Related]
2. Cyclosporine-A induced nephrotoxicity is associated with decreased renal bone morphogenetic protein-7 expression in rats.
Tuğlular S; Gogas Yavuz D; Cakalağaoğlu F; Citak L; Arikan H; Koçak H; Ozener C; Akoğlu E
Transplant Proc; 2004; 36(1):131-3. PubMed ID: 15013323
[TBL] [Abstract][Full Text] [Related]
3. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
4. Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.
Ishimitsu T; Honda T; Ohta S; Akashiba A; Takahashi T; Kameda T; Yoshii M; Minami J; Takahashi M; Ono H; Matsuoka H
Am J Hypertens; 2006 Dec; 19(12):1233-40. PubMed ID: 17161768
[TBL] [Abstract][Full Text] [Related]
5. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
Ferri C; Croce G; Desideri G
Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
[TBL] [Abstract][Full Text] [Related]
6. [The effect of tetramethylpyrazine on the pharmacokinetics of intragastrically administered cyclosporine A in rats].
Liu XL; Tang J; Song J; He J; Xu P; Peng WX
Yao Xue Xue Bao; 2006 Sep; 41(9):882-7. PubMed ID: 17111838
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
8. Effects of benazepril on insulin resistance and glucose tolerance in uremia.
Wu Z; Bao X
Clin Nephrol; 1998 Aug; 50(2):108-12. PubMed ID: 9725782
[TBL] [Abstract][Full Text] [Related]
9. [Effects of long term therapy with angiotensin converting enzyme inhibitor quinapril, antagonist of receptors to angiotensin II valsartan, and combination of quinapril and valsartan in patients with moderate chronic heart failure. Main results of the SADKO-CHF study].
Skvortsov AA; Nasonova SN; Sychev AV; Orlova IaA; Baklanova NA; Masenko VP; Mareev VIu; Belenkov IuN
Kardiologiia; 2006; 46(7):33-51. PubMed ID: 16883264
[TBL] [Abstract][Full Text] [Related]
10. Skeletal muscle capillary responses to insulin are abnormal in late-stage diabetes and are restored by angiotensin-converting enzyme inhibition.
Clerk LH; Vincent MA; Barrett EJ; Lankford MF; Lindner JR
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1804-9. PubMed ID: 17911341
[TBL] [Abstract][Full Text] [Related]
11. [The experimental study of captopril and valsartan on the preventing and treatment of diabetic retinopathy in diabetic mice].
Xie XW; Zhao P
Zhonghua Yan Ke Za Zhi; 2004 Nov; 40(11):770-3. PubMed ID: 15634486
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
13. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
[TBL] [Abstract][Full Text] [Related]
14. Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-arginine methyl ester-induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure-lowering effects of amlodipine and manidipine.
Toba H; Nakagawa Y; Miki S; Shimizu T; Yoshimura A; Inoue R; Asayama J; Kobara M; Nakata T
Hypertens Res; 2005 Aug; 28(8):689-700. PubMed ID: 16392774
[TBL] [Abstract][Full Text] [Related]
15. Exendin-4 improves the oral glucose tolerance in diabetic rats: pancreas regeneration, better function of pancreatic islets, or impaired glucose uptake?
Strauss A; Moskalenko V; Chodnevskaja I; Timm S; Thiede A; Otto C; Ulrichs K
Transplant Proc; 2008 Mar; 40(2):533-5. PubMed ID: 18374122
[TBL] [Abstract][Full Text] [Related]
16. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
Iwai M; Li HS; Chen R; Shiuchi T; Wu L; Min LJ; Li JM; Tsuda M; Suzuki J; Tomono Y; Tomochika H; Mogi M; Horiuchi M
J Pharmacol Exp Ther; 2006 Dec; 319(3):1081-7. PubMed ID: 16990512
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high fat diet.
Weisinger RS; Stanley TK; Begg DP; Weisinger HS; Spark KJ; Jois M
Physiol Behav; 2009 Aug; 98(1-2):192-7. PubMed ID: 19465040
[TBL] [Abstract][Full Text] [Related]
18. [Activation of transforming growth factor-beta1/Smads signal pathway in diabetic cardiomyopathy and effects of valsartan thereon: experiment with rats].
Miao Y; Zhang W; Zhong M; Ma X; Qi TG; Sun H
Zhonghua Yi Xue Za Zhi; 2007 Feb; 87(6):366-70. PubMed ID: 17456374
[TBL] [Abstract][Full Text] [Related]
19. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
He YL; Ligueros-Saylan M; Sunkara G; Sabo R; Zhao C; Wang Y; Campestrini J; Pommier F; Dole K; Marion A; Dole WP; Howard D
J Clin Pharmacol; 2008 Jan; 48(1):85-95. PubMed ID: 17986525
[TBL] [Abstract][Full Text] [Related]
20. Effect of simvastatin given alone and in combination with valsartan or enalapril on blood pressure and the structure of mesenteric resistance arteries and the basilar artery in the genetically hypertensive rat model.
Ledingham JM; Laverty R
Clin Exp Pharmacol Physiol; 2005; 32(1-2):76-85. PubMed ID: 15730439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
